Navigation Links
Opexa Advances Monocyte Derived Islet Technology to Proof of,Principle in stz-induced NOD/SCID Mice

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 27, 2007 - Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company involved in the development and commercialization of cell therapies, presented poster presentations at the 5th International Society for Stem Cell Research Annual Meeting (ISSCR) in Cairns, Queensland, Australia from June 17-20 and at the 13th Annual Meeting of the International Society for Cellular Therapy (ISCT) in Sydney, Australia from June 24-27. The two presentations covered recent research from Opexa's innovative adult stem cell program regarding the development of adult monocyte-derived islets, as beta-cell replacement therapy for diabetes mellitus.

The first presentation was made by Opexa's director of stem cell research, Glenn Winnier, Ph.D. at the ISSCR Annual Meeting and described the differentiation of adult monocyte-derived stem cells (MDSCs) to generate pancreatic endocrine cell clusters known as monocyte-derived islets (MDIs). MDIs express pancreatic specific factors as well as hormones insulin, glucagons and somatostatin in physiological proportions. These studies also demonstrated that MDIs function in a glucose responsive manner when transplanted into diabetic animals. Study animals demonstrate a prolonged reduction (greater than 60 days) in blood glucose levels when MDIs were transplanted under the kidney capsule of stz-induced NOD/SCID mice.

The second presentation, also made by Dr. Winnier, was presented at the ISCT Annual Meeting in Sydney, Australia. The Company's recent adult stem cell research has demonstrated the successful generation of MDIs from insulin-dependent type 1 and type 2 diabetics. These insulin producing islet-like clusters express insulin, glucagon and somatostatin characteristic hormones found in pancreatic islets and function in a glucose responsive manner.

Dr. Winnier commented, "The development of adult MDIs from healthy subjects and the demonstration that these MDIs are functional in vitro and when transplanted into stz-induced NOD/SCID mice is a breakthrough for our adult stem cell program. The differentiation of MDIs derived from MDSCs produced from type 1 and type 2 diabetics is a major advance in the development of a cell replacement therapy for the treatment of diabetes."

"These presentations by Dr. Winnier demonstrate significant advancement of our stem cell development program and serve as proof-of-principle for our adult diabetes mellitus beta-cell replacement therapy development", said David McWilliams, chief executive officer. "The potential use of adult MDSCs for the development of functional MDIs maybe a viable alternative to the development of islet cells derived from embryonic stem cells."

About Opexa Therapeutics

Opexa Therapeutics develops and commercializes cell therapies to treat autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and diabetes. The Company is focused on autologous cellular therapy applications of its proprietary T-cell and stem cell therapies. The Company's lead product, Tovaxin(TM), a T-cell therapy for multiple sclerosis is in Phase IIb trials. The Company holds the exclusive worldwide license for adult multipotent stem cells derived from mononuclear cells of peripheral blood. The technology allows large quantities of monocyte derived stem cells to be produced efficiently for use in autologous therapy, thus circumventing the threat of rejection. The Company is in preclinical development for diabetes mellitus. For more information, visit the Opexa Therapeutics website at www.opexatherapeutics.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements about Opexa Therapeutics' growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. These forwa rd-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Opexa Therapeutics' ability to obtain additional funding, develop its stem cell technologies, achieve its operational objectives, and obtain patent protection for its discoveries, that may cause Opexa Therapeutics' actual results to be materially different from any future results expressed or implied by such forward-looking statements. Opexa Therapeutics undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Contact

Opexa Therapeutics, Inc.
Lynne Hohlfeld, 281-719-3421
lhohlfeld@opexatherapeutics.com
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
Bruce Voss, 310-691-7100
bvoss@lhai.com


'"/>




Related medicine technology :

1. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
2. Opexa Presents Tovaxin Research at Federation of Clinical Immunology Societies Annual Meeting
3. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis
4. Monitoring Patient Glucose Levels: New Advances in software make it easier
5. New Advances in Gastric Diagnostics: Smaller is Better
6. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
7. Peregrine Pharmaceuticals Highlights Significant Advances in the Companys Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting
8. Use of Sequenoms MassARRAY System Leads to Significant Scientific Advances in Understanding Cancer, Diabetes and Drug-Resistant Malaria
9. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
10. Favrille Announces Results From Study Showing Enhanced Activity From Insect Cell-Derived Immunotherapy for Lymphoma
11. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , May 4, 2016 ... across 154 pages, profiling 09 key companies and ... a professional and in-depth study on the current ... basic overview of the industry including definitions, classifications, ... market analysis is provided for the international market ...
(Date:5/3/2016)... Mo. , May 3, 2016 ... Medical Center,s Institute for Advancing Medical Innovation (IAMI) ... commercialize new drugs, diagnostics and medical devices. ... BioNovus Innovations with rights to license, develop and ... "This partnership represents a ...
(Date:5/3/2016)... 2016 Research and Markets has ... Cell Therapy Market Outlook 2020" report to their ... , ,Recombinant technology has improved significantly in past years ... developed in coming years. Many cancer drugs have been ... therapies are also expected to be developed with its ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... Warren L. Smith M.D. , There ... UTIs, have plagued people since the beginning of recorded medical history, and in ... every year. It's not just a matter of inconvenience; bladder infections cost us billions ...
(Date:5/4/2016)... , ... May 03, ... manufacturer of innovative infant and child products, today revealed the non-toxic ... ability to help babies deal with teething pain is just part ... no toxic gels, and are BPA-, PVC-, and phthalate-free. , ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... Patient 2016, a powerful cellular therapy software application that helps blood and ... to patients. , Since Transtem’s initial launch, Mediware has continued to enhance core ...
(Date:5/4/2016)... ... 04, 2016 , ... With the stamp of approval from the United States ... National Cancer Research Month. According to the American Cancer Society (2016) , this ... one in four Americans dying as a result. , With numbers as influential as ...
(Date:5/4/2016)... ... May 04, 2016 , ... DESCO ... acquired Pocono Sterilizer, an equipment sterilization service and sales company located in Pennsylvania. ... medical and research-related equipment and asset management services to the medical and academic ...
Breaking Medicine News(10 mins):